Market Place
Sourcing Support
Santhera Receives NMPA Approval for Agamree in DMD
11 Dec 2024 //
GLOBENEWSWIRE
Santhera Signs Supply Deal for Vamorolone with Ali Al Suwaidi
12 Nov 2024 //
GLOBENEWSWIRE
Santhera Reports Positive Results From LIONHEART Study
01 Oct 2024 //
GLOBENEWSWIRE
Swissmedic Accepts Santhera`s AGAMREE Marketing Application
23 Sep 2024 //
GLOBENEWSWIRE
Santhera Announces H1 2024 Results And Corporate Update
12 Sep 2024 //
GLOBENEWSWIRE
Santhera Enters Distribution Agreement With GENESIS Pharma
10 Sep 2024 //
GLOBENEWSWIRE
Catalyst Pharma Licenses AGAMREE To Kye Pharma For Canada Market
24 Jul 2024 //
GLOBENEWSWIRE
Pfizer`s Setback In DMD Trial Clears Path For Sarepta And Others | DelveInsight
17 Jun 2024 //
PR NEWSWIRE
Santhera announces Early Access Program by partner Sperogenix for DMD treatment
11 Jun 2024 //
PHARMAFILE
Santhera Launches China Early Access For AGAMREE Via Sperogenix
10 Jun 2024 //
GLOBENEWSWIRE
Santhera Announces NDA for vamorolone in DMS Accepted and GPR by China
27 Mar 2024 //
GLOBENEWSWIRE
Santhera™s Partner Catalyst Launches AGAMREE® (Vamorolone) in the United States
14 Mar 2024 //
GLOBENEWSWIRE
Catalyst Announces Publication of Santhera`s VISION-DMD Vamorolone Study Results
21 Feb 2024 //
GLOBENEWSWIRE
Santhera Announces Publication of Efficacy and Tolerability Data with Vamorolone
14 Feb 2024 //
GLOBENEWSWIRE
Santhera Launches AGAMREE in Germany as First Market for DMD
16 Jan 2024 //
GLOBENEWSWIRE
Santhera Receives Approval for AGAMREE as a Treatment for DMD
12 Jan 2024 //
GLOBENEWSWIRE
Santhera’s Agamree gains EU approval for Duchenne muscular dystrophy
19 Dec 2023 //
GLOBENEWSWIRE
Santhera`s drug gets US FDA nod for rare muscular dystrophy
27 Oct 2023 //
GLOBENEWSWIRE
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE
13 Oct 2023 //
GLOBENEWSWIRE
Catalyst Pharma Acquires Exclusive North American License For Vamorolone
19 Jul 2023 //
GLOBENEWSWIRE
Santhera Announces Closing of Agreement with Catalyst for Vamorolone
19 Jul 2023 //
GLOBENEWSWIRE
Catalyst to License North American Rights to Vamorolone for DMD from Santhera
20 Jun 2023 //
GLOBENEWSWIRE
Catalyst licenses Santhera Pharma’s vamorolone in North America
20 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
Santhera Grants Exclusive North America License for Vamorolone to Catalyst
20 Jun 2023 //
GLOBENEWSWIRE
Santhera and ReveraGen Announce FDA Acceptance of NDA for Vamorolone
09 Jan 2023 //
GLOBENEWSWIRE
Santhera seeks speedy FDA review of Duchenne drug vamorolone
28 Oct 2022 //
PHARMAPHORUM
Santhera Submits Marketing Authorization Application to the EMAyfor Vamorolone
03 Oct 2022 //
GLOBENEWSWIRE
Santhera submits marketing authorisation application for vamorolone
03 Oct 2022 //
PHARMATIMES
JAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone
31 Aug 2022 //
GLOBENEWSWIRE
Santhera and ReveraGen Announce 1st Participant Dosed in FDA-funded PII study
22 Aug 2022 //
GLOBENEWSWIRE
Santhera Updates on Ongoing NDA Submission for Vamorolone
28 Jun 2022 //
GLOBENEWSWIRE
Santhera, ReveraGen to Present Efficacy & Safety Data with Vamorolone at MDA
14 Mar 2022 //
GLOBENEWSWIRE
Santhera Enters into Excl License Agreement with Sperogenix for Vamorolone
03 Jan 2022 //
GLOBENEWSWIRE
Santhera, ReveraGen announce positive topline results with vamorolone
24 Nov 2021 //
PHARMABIZ
Santhera & ReveraGen Announce +veTopline Results with Vamorolone
23 Nov 2021 //
GLOBENEWSWIRE
Santhera und ReveraGen geben erfolgreiches FDA-Pre-NDA-Meeting für Vamorolone
17 Nov 2021 //
GLOBENEWSWIRE
Santhera &ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone
17 Nov 2021 //
GLOBENEWSWIRE
Santhera Announces Publication on Molecular Distinctions of Vamorolone
13 Sep 2020 //
GLOBENEWSWIRE
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone
03 Sep 2020 //
GLOBENEWSWIRE
Santhera Announces Completion of ReveraGen’s Long-Term Study with Vamorolone
01 Jun 2020 //
GLOBENEWSWIRE
ReveraGen`s Anti-Inflammatory Demonstrates Positive Results
07 Oct 2019 //
BIOSPACE
ReveraGen reports positive data for vamorolone in DMD
28 Aug 2019 //
CLINICALTRIALSARENA
Idorsia sheds surplus DMD therapy to Santhera
21 Nov 2018 //
FIERCE BIOTECH
